Orsaria Paolo, Varvaras Dimitrios, Vanni Gianluca, Pagnani Giampiero, Scaggiante Jacopo, Frusone Federico, Granai Alessandra Vittoria, Petrella Giuseppe, Buonomo Oreste Claudio
Department of Surgery, Tor Vergata University Hospital, 00133 Rome, Italy.
Int J Breast Cancer. 2014;2014:469803. doi: 10.1155/2014/469803. Epub 2014 Feb 11.
Even in the era of gene-expression profiling, the nodal status still remains the primary prognostic discriminant in breast cancer patients. The exclusion of node involvement using noninvasive methods could reduce the rate of axillary surgery, thereby preventing from suffering complications. However, lymphatic mapping with sentinel node biopsy (SNB) is one of the most interesting recent developments in surgical oncology. Optimization of procedure could be implemented by dual mapping injection site skills, resection of all hot or blue nodes through tracer combination, and improvement in atypical drainage patterns mapping. This anatomical analysis suggests safety measures in patients with high probability of node metastasis through a renewed interest in surgical management. The perspective of a guided axillary sampling (GAS) could represent a potential development of recent anatomical and functional acquisitions, offering a dynamic technique shared according to clinical and anatomical disease parameters. Furthermore, the surgical staging procedures may adopt a conservative approach through the evaluation of upper arm lymphatics, thus defining a functional model aimed at the reduction of short- and long-term adverse events. Quality results in breast cancer surgery need to generate oncological safety devoid of complications through renewed clinical experience.
即使在基因表达谱分析的时代,淋巴结状态仍然是乳腺癌患者主要的预后判别因素。使用非侵入性方法排除淋巴结受累情况可以降低腋窝手术率,从而避免并发症的发生。然而,前哨淋巴结活检(SNB)的淋巴绘图是外科肿瘤学领域近年来最引人关注的进展之一。可以通过双绘图注射部位技术、通过示踪剂组合切除所有热结节或蓝染结节以及改进非典型引流模式绘图来优化手术过程。这种解剖学分析通过重新关注手术管理,为高淋巴结转移概率的患者提出了安全措施。引导性腋窝取样(GAS)的观点可能代表了近期解剖学和功能学成果的潜在发展方向,提供了一种根据临床和解剖学疾病参数共享的动态技术。此外,手术分期程序可以通过评估上臂淋巴管采取保守方法,从而确定一个旨在减少短期和长期不良事件的功能模型。乳腺癌手术的优质结果需要通过更新临床经验,实现无并发症的肿瘤学安全性。